TOKYO -- Eisai said Thursday it has agreed to collaborate with U.S. counterpart Merck on development and marketing of the Japanese pharmaceutical company's cancer drug Lenvima, a deal that also brings a timely infusion of cash.
Business deals
Eisai teams with Merck to boost sales of cancer drug
Japanese drugmaker bets future on using payments to devise dementia treatments
